MX2012006878A - Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc). - Google Patents
Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc).Info
- Publication number
- MX2012006878A MX2012006878A MX2012006878A MX2012006878A MX2012006878A MX 2012006878 A MX2012006878 A MX 2012006878A MX 2012006878 A MX2012006878 A MX 2012006878A MX 2012006878 A MX2012006878 A MX 2012006878A MX 2012006878 A MX2012006878 A MX 2012006878A
- Authority
- MX
- Mexico
- Prior art keywords
- copd
- combination therapy
- formoterol
- glycopyrronium bromide
- formulation further
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 2
- 229960002848 formoterol Drugs 0.000 abstract 2
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/003—Adding propellants in fluid form to aerosol containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B7/00—Closing containers or receptacles after filling
- B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
- B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
- B65B7/2842—Securing closures on containers
- B65B7/285—Securing closures on containers by deformation of the closure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Mechanical Engineering (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
La invención se relaciona con una formulación en aerosol que es apropiada para administrar a pacientes de EPOC por medio de un inhalador presurizado de dosis medida (pMDI), que comprende bromuro de glicopirronio en combinación con formoterol. La formulación comprende además un propelente de HFA, un cosolvente, y una cantidad de ácido inorgánico que es suficiente para estabilizar tanto el componente de bromuro de glicopirronio como el de formoterol. Opcionalmente la formulación comprende además dipropionato de beclometasona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180671 | 2009-12-23 | ||
| PCT/EP2010/070479 WO2011076843A2 (en) | 2009-12-23 | 2010-12-22 | Combination therapy for copd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012006878A true MX2012006878A (es) | 2012-07-04 |
Family
ID=42107420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006878A MX2012006878A (es) | 2009-12-23 | 2010-12-22 | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc). |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US20110150782A1 (es) |
| EP (1) | EP2515855B3 (es) |
| JP (2) | JP5914354B2 (es) |
| KR (2) | KR101757951B1 (es) |
| CN (2) | CN104055765B (es) |
| AR (2) | AR079726A1 (es) |
| AU (3) | AU2010334859A1 (es) |
| BR (1) | BR112012015337B8 (es) |
| CA (1) | CA2785321C (es) |
| CL (1) | CL2012001705A1 (es) |
| CO (1) | CO6541628A2 (es) |
| CY (2) | CY1115116T1 (es) |
| DK (1) | DK2515855T6 (es) |
| EA (2) | EA027778B1 (es) |
| ES (1) | ES2468840T7 (es) |
| FI (2) | FI2515855T6 (es) |
| GE (1) | GEP20156311B (es) |
| HR (1) | HRP20140582T4 (es) |
| HU (1) | HUS1800001I1 (es) |
| IL (1) | IL260932B (es) |
| LT (1) | LTC2515855I2 (es) |
| LU (1) | LUC00060I2 (es) |
| MA (1) | MA33823B1 (es) |
| MX (1) | MX2012006878A (es) |
| MY (1) | MY156949A (es) |
| NL (1) | NL300923I2 (es) |
| NO (1) | NO2018001I2 (es) |
| NZ (1) | NZ600790A (es) |
| PE (2) | PE20121396A1 (es) |
| PH (1) | PH12012501066A1 (es) |
| PL (1) | PL2515855T6 (es) |
| PT (1) | PT2515855E (es) |
| RS (1) | RS53391B2 (es) |
| SG (1) | SG181868A1 (es) |
| SI (1) | SI2515855T1 (es) |
| TN (1) | TN2012000269A1 (es) |
| TW (1) | TWI495468B (es) |
| UA (1) | UA113832C2 (es) |
| WO (1) | WO2011076843A2 (es) |
| ZA (1) | ZA201204615B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2785321C (en) * | 2009-12-23 | 2018-08-21 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| MX340264B (es) * | 2009-12-23 | 2016-07-04 | Chiesi Farm Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. |
| ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| RU2013142268A (ru) * | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| CN103874483B (zh) | 2011-10-11 | 2017-09-12 | 奇斯药制品公司 | 包衣了脂肪酸的β‑激动剂的晶体微粒 |
| JP2016503390A (ja) * | 2012-10-23 | 2016-02-04 | シプラ・リミテッド | 医薬組成物 |
| PT3019153T (pt) * | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
| ES2666905T4 (es) * | 2013-12-30 | 2018-06-07 | Chiesi Farmaceutici S.P.A. | Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol |
| SI3089735T1 (sl) | 2013-12-30 | 2018-10-30 | Chiesi Farmaceutici S.P.A. | Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| TWI731891B (zh) | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法 |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3436115B1 (en) | 2016-03-31 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Aerosol inhalation device |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| PE20191043A1 (es) * | 2016-09-19 | 2019-08-06 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
| ES2877575T3 (es) | 2016-09-19 | 2021-11-17 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende salmeterol |
| ES2956521T3 (es) * | 2016-09-19 | 2023-12-22 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de tiotropio |
| CN110582269B (zh) | 2017-05-11 | 2023-02-28 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
| KR20220155609A (ko) | 2017-05-11 | 2022-11-23 | 키에시 파르마슈티시 엣스. 피. 에이. | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 |
| MA52756A (fr) * | 2018-06-04 | 2021-04-14 | Lupin Inc | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression |
| CN114502146A (zh) * | 2019-12-02 | 2022-05-13 | 奇斯药制品公司 | 用于加压定量吸入器的不锈钢罐 |
| US20230270754A1 (en) | 2020-07-31 | 2023-08-31 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| CA3193038A1 (en) | 2020-10-09 | 2022-04-14 | Enrico Zambelli | A pharmaceutical formulation for pressurised metered dose inhaler |
| WO2023227782A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| CN119255820A (zh) | 2022-05-27 | 2025-01-03 | 奇斯药制品公司 | 用于加压定量吸入器的药物制剂 |
| WO2023227781A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| WO1994013263A1 (en) | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
| ATE283033T1 (de) | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
| EP1102579B1 (de) * | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| BR0015884A (pt) * | 2000-05-22 | 2003-07-08 | Chiesi Farma Spa | Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| DE50211045D1 (de) | 2001-03-30 | 2007-11-22 | Jagotec Ag | Medizinische aerosolformulierungen |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| KR100947409B1 (ko) | 2002-03-01 | 2010-03-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 포모테롤 초미세 조성물 |
| EP1575588A1 (en) | 2002-12-16 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Tiotropium containing hfc solution formulations |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| PT1713473E (pt) | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| DE602005007708D1 (de) * | 2004-02-06 | 2008-08-07 | Meda Pharma Gmbh & Co Kg | Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1616567A1 (en) | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| GB0505545D0 (en) | 2005-03-17 | 2005-04-27 | Glaxo Group Ltd | Inhalation devices |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| KR20080032136A (ko) | 2005-08-01 | 2008-04-14 | 아스트라제네카 아베 | 흡입기 밸브 |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| NZ568349A (en) | 2005-12-21 | 2011-05-27 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| US8618160B2 (en) | 2007-10-18 | 2013-12-31 | Rose U | Topical glycopyrrolate formulations |
| AU2010258751A1 (en) * | 2009-06-09 | 2012-02-02 | Sunovion Respiratory Development Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| ES2467928T3 (es) | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| MX340264B (es) * | 2009-12-23 | 2016-07-04 | Chiesi Farm Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. |
| ES2468835T3 (es) | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| CA2785321C (en) * | 2009-12-23 | 2018-08-21 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| PT3019153T (pt) * | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
| ES2666905T4 (es) * | 2013-12-30 | 2018-06-07 | Chiesi Farmaceutici S.P.A. | Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol |
| SI3089735T1 (sl) * | 2013-12-30 | 2018-10-30 | Chiesi Farmaceutici S.P.A. | Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2010
- 2010-12-22 CA CA2785321A patent/CA2785321C/en active Active
- 2010-12-22 TW TW099145166A patent/TWI495468B/zh active
- 2010-12-22 NZ NZ600790A patent/NZ600790A/en unknown
- 2010-12-22 JP JP2012545323A patent/JP5914354B2/ja active Active
- 2010-12-22 SI SI201030654T patent/SI2515855T1/sl unknown
- 2010-12-22 EA EA201590179A patent/EA027778B1/ru active Protection Beyond IP Right Term
- 2010-12-22 AU AU2010334859A patent/AU2010334859A1/en not_active Abandoned
- 2010-12-22 PL PL10799030.1T patent/PL2515855T6/pl unknown
- 2010-12-22 KR KR1020127015996A patent/KR101757951B1/ko active Active
- 2010-12-22 PT PT107990301T patent/PT2515855E/pt unknown
- 2010-12-22 AR ARP100104922A patent/AR079726A1/es not_active Application Discontinuation
- 2010-12-22 KR KR1020177009412A patent/KR20170040392A/ko not_active Ceased
- 2010-12-22 CN CN201410289445.6A patent/CN104055765B/zh active Active
- 2010-12-22 EP EP10799030.1A patent/EP2515855B3/en active Active
- 2010-12-22 PH PH1/2012/501066A patent/PH12012501066A1/en unknown
- 2010-12-22 WO PCT/EP2010/070479 patent/WO2011076843A2/en not_active Ceased
- 2010-12-22 EA EA201290375A patent/EA021917B1/ru active Protection Beyond IP Right Term
- 2010-12-22 DK DK10799030.1T patent/DK2515855T6/da active
- 2010-12-22 MX MX2012006878A patent/MX2012006878A/es active IP Right Grant
- 2010-12-22 BR BR112012015337A patent/BR112012015337B8/pt active IP Right Grant
- 2010-12-22 PE PE2012000865A patent/PE20121396A1/es not_active Application Discontinuation
- 2010-12-22 PE PE2016000787A patent/PE20160853A1/es unknown
- 2010-12-22 UA UAA201207626A patent/UA113832C2/uk unknown
- 2010-12-22 SG SG2012046157A patent/SG181868A1/en unknown
- 2010-12-22 CN CN201080058048.8A patent/CN102665679B/zh active Active
- 2010-12-22 ES ES10799030T patent/ES2468840T7/es active Active
- 2010-12-22 HR HRP20140582TT patent/HRP20140582T4/hr unknown
- 2010-12-22 GE GEAP201012756A patent/GEP20156311B/en unknown
- 2010-12-22 MY MYPI2012002844A patent/MY156949A/en unknown
- 2010-12-22 RS RS20140338A patent/RS53391B2/sr unknown
- 2010-12-23 US US12/977,159 patent/US20110150782A1/en not_active Abandoned
-
2012
- 2012-05-29 TN TNP2012000269A patent/TN2012000269A1/en unknown
- 2012-06-01 CO CO12092198A patent/CO6541628A2/es unknown
- 2012-06-14 MA MA34966A patent/MA33823B1/fr unknown
- 2012-06-21 CL CL2012001705A patent/CL2012001705A1/es unknown
- 2012-06-21 ZA ZA2012/04615A patent/ZA201204615B/en unknown
-
2014
- 2014-05-29 CY CY20141100382T patent/CY1115116T1/el unknown
-
2015
- 2015-07-29 US US14/812,190 patent/US10159645B2/en active Active
-
2016
- 2016-04-04 JP JP2016075136A patent/JP6283388B2/ja active Active
- 2016-09-27 AU AU2016234895A patent/AU2016234895B2/en active Active
-
2017
- 2017-12-22 CY CY2017047C patent/CY2017047I1/el unknown
- 2017-12-29 FI FIEP10799030.1T patent/FI2515855T6/fi active
- 2017-12-29 FI FIC20170064C patent/FIC20170064I1/fi unknown
-
2018
- 2018-01-05 HU HUS1800001C patent/HUS1800001I1/hu unknown
- 2018-01-10 NO NO2018001C patent/NO2018001I2/no unknown
- 2018-01-10 LU LU00060C patent/LUC00060I2/fr unknown
- 2018-01-11 LT LTPA2018001C patent/LTC2515855I2/lt unknown
- 2018-01-12 NL NL300923C patent/NL300923I2/en unknown
- 2018-04-30 AU AU2018202998A patent/AU2018202998A1/en not_active Abandoned
- 2018-08-01 IL IL260932A patent/IL260932B/en active IP Right Grant
- 2018-10-16 US US16/161,427 patent/US11389401B2/en active Active
-
2019
- 2019-08-02 AR ARP190102199A patent/AR115897A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000269A1 (en) | Combination therapy for copd | |
| WO2011076841A3 (en) | Combination therapy for copd | |
| GEP20166479B (en) | Aerosol formulation for copd | |
| WO2012016845A3 (en) | Pharmaceutical formulation comprising a phosphodiesterase inhibitor | |
| CO2022012449A2 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| MX2013012975A (es) | Composiciones farmaceuticas. | |
| TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
| MX357619B (es) | Inhalador que comprende una composición que contiene tiotropio. | |
| GEP20227418B (en) | Combination therapy for copd | |
| MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| WO2012040228A3 (en) | Aerosol composition for administering drugs | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| CO2023004162A2 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| NZ591174A (en) | Metered dose inhaler | |
| WO2011076840A3 (en) | Aerosol formulation for copd | |
| MX2024014385A (es) | Formulacion farmaceutica para inhalador presurizado de dosis medidas | |
| TH127043A (th) | ผลิตภัณฑ์รวมสำหรับบำบัด copd | |
| BR102012008322B8 (pt) | formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |